Bactericidal activity of levofloxacin against Mycoplasma pneumoniae
Abstract
Departments of 1Microbiology and 2Pathology, University of Alabama at Birmingham, Birmingham, AL, USA Sir, Mycoplasma pneumoniae infects persons of all age groups and is responsible for as much as 25–50% of community-acquired pneumonias.1 It is also a common cause of tracheobronchitis. Fatal pneumonias and disseminated infections involving the central nervous system, joints and other organs sometimes occur.1 Disease may be especially severe and prolonged in persons who are immunosuppressed.1 Cost and limited availability of diagnostic tests mandate that treatment for M. pneumoniae infections must be given empirically in most settings. Macrolides and tetracyclines possess bacteriostatic activity, but fluoroquinolones represent the only drugs likely to be bactericidal against this organism.2 Levofloxacin has been shown to be active in vitro against M. pneumoniae.2–6 This study was undertaken to evaluate the in vitro activity of levofloxacin against a large number of recent clinical isolates of M. pneumoniae recovered from patients with proven respiratory tract disease and to assess its bactericidal activities against a subgroup of these organisms by determining MBCs and carrying out time–kill assays.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.